J&J Gets Into The Anti-TSLP Game With Proteologix Buyout

 
• By Joseph Haas

The privately held biotech will bring J&J a pair of bispecific antibodies expected to target multiple pathologic pathways in atopic dermatitis and asthma.

Deal (Sergey Nivens/Shutterstock.com)
J&J makes its second biopharma acquisition of the year with Proteologix deal

More from Deals

More from Business